Enorama Pharma AB (OSTO:ERMA) Other Financing: kr-0.02 Mil (TTM As of Mar. 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.26
GF Value kr0.41
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Other Financing?

Enorama Pharma AB OSTO:ERMA -4.14% 28 Other Financing is kr-0.02 Mil as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.41 (Possible Value Trap). The stock has 4 warning signs investors should review.

Enorama Pharma AB's Other Financing for the three months ended in Mar. 2026 was kr0.00 Mil.

Enorama Pharma AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.02 Mil.

Enorama Pharma AB Other Financing Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Other Financing Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.79 -1.57 0.00 -4.68 -0.61

Enorama Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -0.02 0.00 0.00 0.00
OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr-0.02 Mil mean?
Enorama Pharma AB (OSTO:ERMA) has a Other Financing of kr-0.02 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's Other Financing too high?
Enorama Pharma AB's current Other Financing is kr-0.02 Mil. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Other Financing compare to ZTS and UTHR?
Enorama Pharma AB's Other Financing of kr-0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Enorama Pharma AB and its competitors. Enorama Pharma AB's current Other Financing is kr-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.26 — trading 37.8% below its estimated fair value. The current Other Financing is kr-0.02 Mil. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Other Financing is kr-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.26 is trading 37.8% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Possible Value Trap.

Key valuation signals for OSTO:ERMA:

  • Other Financing: kr-0.02 Mil
  • GF Value™: kr0.41 vs. price of kr0.26 (37.8% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.26
Price
kr0.41
GF Value